China Medical Molecular Sieve Oxygen Generator Industry Development Report

The global medical molecular sieve oxygen generator industry maintained steady growth in 2025, driven primarily by accelerating population aging, rising prevalence of chronic respiratory diseases, and continuous investment in the development of primary healthcare systems. As the dominant oxygen production solution, pressure swing adsorption (PSA) technology has seen growing penetration in the medical field due to its low energy consumption, stable operation, and high oxygen purity. In 2025, industry standards were further upgraded, with multiple technical specifications and product safety requirements revised, directly driving the iteration of low‑noise, intelligent IoT‑enabled, and highly integrated products. Industrial policies have explicitly supported the expansion of home healthcare and community health services, serving as a key catalyst for market expansion.

In terms of market size, the global medical molecular sieve oxygen generator market recorded a near double‑digit annual growth rate between 2024 and 2025, with the Chinese market expanding significantly faster than the global average. The widespread adoption of home healthcare and the extensive deployment of equipment in county‑level medical consortiums have emerged as critical growth engines. Regarding product categories, demand for high‑flow therapeutic devices and portable units has risen notably: the former is designed for patients with chronic obstructive pulmonary disease (COPD) and hypoxemia, while the latter has benefited from the expansion of outdoor emergency and mobile home care scenarios.

The industry is in a growth phase with high technological maturity and clear innovation priorities, mainly focused on improving adsorbent material efficiency, optimizing system energy consumption, and developing intelligent control algorithms. Although European and American enterprises hold a large share of the international market, Chinese manufacturers have continuously expanded their global presence through supply chain integration and cost advantages. Amid a stable international trade environment in 2025, export business of Chinese companies has recovered noticeably, with particularly strong performance in countries and regions along the Belt and Road.